Positions for Accuray Inc (NASDAQ:ARAY)

In Q4 2018 Accuray Inc (NASDAQ:ARAY) big money sentiment increased to 1.92, according to SEC filings. So its up 0.77, from 2018Q3’s 1.15. 71 investment professionals opened new and increased holdings, while 37 cut down and sold their stakes in Accuray Inc so the sentiment is positive. These funds own 66.74 million shares, that’s up from 65.64 million shares in 2018Q3. Funds holding Accuray Inc in top 10 changed to 0 from 0 for the same number . In total 9 funds closed positions, 28 reduced and 39 increased. Also 32 funds bought new Accuray Inc stakes.

Most Accuray Inc Shareholders

As of Q4 2018 Lapides Asset Management Llc has 1.36% invested in Accuray Inc. As of Q4 2018, 561,634 shares of Accuray Inc are owned by Adirondack Research & Management Inc.. Heartland Advisors Inc reported 3.44 million shares. Endurant Capital Management Lp revealed 455,018 shares position in Accuray Inc. The Georgia-based fund Vident Investment Advisory Llc looks positive on Accuray Inc, owning 1.89 million shares.

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body.The firm is valued at $407.76 million. The firm offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.Last it reported negative earnings. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally.

ARAY reached $4.64 during the last trading session after $0.07 change.Currently Accuray Incorporated is downtrending after 3.02% change in last March 26, 2018. ARAY has also 297,632 shares volume. The stock underperformed the S&P500 by 7.39%.

On April, 29 Accuray Incorporated (NASDAQ:ARAY)’s earnings release is expected by WallStreet, Zacks reports. The EPS diference is $0.06 or 60.00 % up from last years number. Previous year: $-0.1; Analysts forcast: $-0.04. Last quarter $-0.05 EPS was reported. Analysts forecasts -20.00 % EPS growth this quarter.

Price T Rowe Associate Md has 40,024 shs for 0% of their capital. Amalgamated Comml Bank reported 12,716 shs stake. Aqr Capital Mgmt Limited Liability stated it has 45,901 shs or 0% of all its holdings. Ameriprise Financial Inc reported 0% stake. Federated Pa invested 0% of its capital in Accuray Incorporated (NASDAQ:ARAY). Blackrock Inc invested in 0% or 8.29 million shs. Citadel Advsrs Ltd Liability Corp reported 535,925 shs or 0% of all its holdings. Meeder Asset Inc invested 0% of its capital in Accuray Incorporated (NASDAQ:ARAY). Boston Prns stated it has 0% of its capital in Accuray Incorporated (NASDAQ:ARAY). Teton Advsr reported 0.01% stake. 455,018 were accumulated by Endurant Management L P. State Board Of Administration Of Florida Retirement Sys accumulated 71,909 shs. Invesco Limited has invested 0% of its capital in Accuray Incorporated (NASDAQ:ARAY). Millennium Limited Liability Corporation invested 0.01% in Accuray Incorporated (NASDAQ:ARAY). Heartland Advsr Inc has invested 0.97% of its capital in Accuray Incorporated (NASDAQ:ARAY).

Accuray Incorporated registered $169,428 net activity with 2 insider buys and 8 insider sales since October 2, 2018. 1,846 shs were sold by Chew Jesse, worth $7,819. LEVINE JOSHUA sold $201,521 worth of stock or 43,257 shs. The insider WHITTERS JOSEPH E bought 25,000 shs worth $117,000. On Tuesday, October 2 Shares for $39,255 were sold by Hamamatsu Shigeyuki.

For more Accuray Incorporated (NASDAQ:ARAY) news released recently go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Notable Thursday Option Activity: ARAY, ADTN, MHK – Nasdaq” released on January 24, 2019, “Health Care Sector Update for 01/29/2019: ARAY, TRVN, ABBV, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” on January 29, 2019, “CURE Pharmaceutical Expands US DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant – Nasdaq” with a publish date: March 12, 2019, “Earnings Reaction History: Accuray Incorporated, 50.0% Follow-Through Indicator, 9.2% Sensitive – Nasdaq” and the last “Accuray’s (ARAY) Q2 Loss Narrows, Radixact Demand Shoots Up – Nasdaq” with publication date: January 23, 2019.